A 10-week trial of high-intensity atorvastatin therapy demonstrated increased insulin resistance and compensatory insulin secretion, suggesting a shift toward glucose intolerance in susceptible individuals (Abbasi et al., 2021). This evidence concerns the gene INS and Glucose intolerance.